Login to Your Account



ANALYST: BLOCKBUSTER POTENTIAL

Investors eyeing Aerie Pharma's Roclatan after positive phase IIb glaucoma data

By Karen Pihl-Carey
Staff Writer

Wednesday, June 25, 2014
Reducing intraocular pressure (IOP) in a phase IIb trial and providing new hope for glaucoma patients, Aerie Pharmaceuticals Inc.'s quadruple-acting combination drug Roclatan nailed its primary endpoint by showing statistically significant superiority over each of its components.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription